

**Exposure- and genetically driven epigenetic associations with lifetime cannabis use.**

Stephanie N. Giamberardino<sup>1</sup>, Linran Zhou<sup>1</sup>, Jesse A. Marks<sup>1</sup>, Kaitlyn G. Lawrence<sup>2</sup>, Zongli Xu<sup>2</sup>, Jack A. Taylor<sup>2</sup>, Dale P. Sandler<sup>2</sup>, Aino E. Heikkinen<sup>3</sup>, Mikaela Hukkanen<sup>3</sup>, Miina Ollikainen<sup>3</sup>, Jaakko Kaprio<sup>3</sup>, Laura J. Bierut<sup>4</sup>, Jenny van Dongen<sup>5</sup>, Dorret I. Boomsma<sup>5</sup>, Youshu Cheng<sup>6</sup>, Ke Xu<sup>6,7</sup>, Sergio Villicaña Muñoz<sup>8</sup>, Jordana T. Bell<sup>8</sup>, Dana B. Hancock<sup>1</sup>, Eric O. Johnson<sup>1,9</sup>, Fang Fang<sup>1</sup>

<sup>1</sup>GenOmics and Translational Research Center, RTI International;

<sup>2</sup>Epidemiology Branch, National Institute of Environmental Health Sciences;

<sup>3</sup>Institute for Molecular Medicine Finland, University of Helsinki;

<sup>4</sup>Department of Psychiatry, Washington University School of Medicine;

<sup>5</sup>Department of Biological Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam;

<sup>6</sup>Department of Psychiatry, Yale School of Medicine;

<sup>7</sup>VA Connecticut Healthcare System;

<sup>8</sup>Department of Twin Research & Genetic Epidemiology, King's College London;

<sup>9</sup>Fellow Program, RTI International

Cannabis use, though prevalent, may be poorly reported, making it important to find a reliable biomarker for quantifying lifetime use. Leukocyte DNA methylation (DNAm) may serve as a viable and sensitive biomarker of cannabis use. Previously, we identified DNAm associations with cannabis use, but DNAm levels can also be influenced by genetic variation. Here, we identify genetically-associated DNAm signals, with the aim to exclude these effects when characterizing DNAm biomarkers of cannabis use. We identified *cis*-methylation quantitative trait loci (*cis*-meQTL) for cannabis-associated CpGs identified in our prior EWAS. We conducted within-ancestry (African and European) inverse variance-weighted meta-analyses of SNP-CpG associations generated within cohort using the Matrix eQTL software. Amongst the N=1,353 CpGs meta-analyzed in either ancestry group, we identified *cis*-meQTL (random effects p-value <  $1 \times 10^{-5}$ ) for N<sub>Afr</sub>=244 and N<sub>Eur</sub>=386 CpGs, with N=154 CpGs having *cis*-meQTL identified in both groups. Using location-based enrichment testing, we found that CpGs with *cis*-meQTL were significantly (FDR adjusted p-value<0.05) enriched in CpG shore regions (FDR p<sub>Afr</sub>=0.001, FDR p<sub>Eur</sub>= $8.36 \times 10^{-7}$ ) and depleted in open sea regions (FDR p<sub>Afr</sub>=0.001, FDR p<sub>Eur</sub>=0.043), compared to the total set of meta-analyzed cannabis-associated CpGs. For the CpGs with *cis*-meQTL identified in the African- and European-ancestry meta-analyses, 89% and 95%, respectively, of these CpGs had previously detected *cis*-meQTL in the GoDMC study, the largest meQTL database with predominantly European ancestry samples. These results suggest an influence of unaccounted-for genetic variation in prior cannabis CpG associations. Excluding these genotype-related CpGs will enhance the power to identify cannabis exposure-associated DNAm biomarkers.